Gastric biopsy sampling could affect accuracy of Helicobacter pylori clarithromycin resistance assessment due to coexistence of susceptible and resistant strains (i.e. heteroresistance) either in same gastric site (intraniche) or in two different gastric sites (interniche). This study aimed to assess differences in the H. pylori clarithromycin resistance prevalence in relation to the gastric biopsy sampling by using Taqman-real time polymerase chain reaction (PCR). The study enrolled 137 patients. Primary clarithromycin resistance was observed in 15 isolates exclusively in antrum, in 7 cases exclusively in gastric body, and in 3 patients in both gastric sites. The overall prevalence of clarithromycin resistance was 13.1% by using exclusively antral biopsies, and 18.2% by using biopsies from both gastric sites. Moreover, intra-niche heteroresistance was observed in 19 (76%) out of 25 patients harbouring resistant strains. Our data found a heterogeneous distribution of resistant H. pylori strains in the stomach. Similarly to culture, gastric biopsies from both antrum and gastric body are needed to increase the accuracy of PCR-based methods for clarithromycin resistance assessment.
Introduction
Primary clarithromycin resistance is widely recognized as the main factor reducing efficacy of eradication therapies. 1 Unfortunately, it is difficult to culture Helicobacter pylori from gastric biopsies. 2 Therefore, different polymerase chain reaction (PCR)-based techniques have been introduced to overcome some limits of bacterial culture for clarithromycin resistance assessment. Besides a very high accuracy (98%), 3, 4 these techniques allow to assess a singular condition, i.e. the heteroresistance. 5 Such a status describes the coexistence of resistant and susceptible bacterial strains towards to a specific antibiotic in the same patient. Heteroresistance may be either intraniche (coexistent susceptible and resistant strains in the same gastric site) or interniche (separate susceptible and resistant strains in different gastric site, i.e. antrum and gastric body). Based on the latter possibility, antibiotic assessment by using in only antral biopsies -as usually performed for bacterial culture -may underestimate the actual H. pylori resistance status. 6, 7 This study aimed to assess primary clarithromycin resistance in H. pylori strains separately in antral and gastric body mucosa biopsies.
Case Report

Patients
The study enrolled consecutive, >18 years old patients never previously treated for H. pylori infection who underwent upper endoscopy due to dyspeptic symptoms. All patients underwent endoscopy with biopsies, including 2 specimens from the antrum and 2 from the gastric body. All patients gave informed consent to participate into the study.
TaqMan real time polymerase chain reaction
DNAs were extracted by using the NucleoSpinnTissue (Macherey-Nagel GmbH&Co, Germany) according to manufacturer's instructions, applied on embedded-paraffined sections (10μ) which constitutes a reliable substrate for DNA analysis likewise fresh material. 8 The A2142C, A2142G and A2143G point mutations in the 23S rRNA involved in H. pylori clarithromycin resistance were detected by molecular analysis after DNA extraction by using a TaqMan real-time PCR, as previously described and validated. 8 Biopsies from antral were analyzed separately from those of gastric body mucosa.
Results
The study enrolled 137 patients (Mean age: 48±12; M/F: 54/83) with non-ulcer dyspepsia. Primary clarithromycin resistance was detected exclusively in gastric antrum in 15 isolates (13 with A2143G a 2 with A2142G point mutation), exclusively in gastric body in 7 patients (6 A2143G and 1 with A2142G point mutation), and in both sites in 3 cases (2 A2143G, 1 A2142G). The inter-niche heteroresistance was found in 22 (16%; 95% CI=9.9-22.2) out of 137 patients, including 15 patients with resistant strains in antrum and susceptible strains in gastric body, and 7 patients with the reverse condition. By using exclusively biopsies from antral mucosa primary clarithromycin resistance was detected in 18 (13.1%; 95% CI: 7.4-18.7) out of 137 patients. Such a value increases to 18.2% (95% CI: 11.7-24.7) by adding gastric body biopsies assessment. As far as intraniche heteroresistance is regarded, a heterogeneous bacterial population was observed in 9 (60%) out of 15 in gastric antrum, in all 7 (100%) patients in gastric body, and in all 3 (100%) with bacterial resistance detected in both gastric sites. Consequently, the intraniche heteroresistance was detected 19 (76%; 95% CI: 59.2-92.7) out of 25 patients harbouring resistant strains, with a overall prevalence of heteroresistance status of 13.8%. Finally, the A2143G was the most prevalent point mutation, being present in 21 (84%; 95% CI: 69.6-98.3) out of 25 resistant strains, followed by the A2142G point mutation present in the remaining 4 isolates.
Discussion
Novel bio-molecular PCR-based tools are able to overcome some limits of bacterial culture in assessing H. pylori clarithromycin resistance. 3, 4 In detail, PCR-based methods allow to identify even minimal traces of resistant strains among a large susceptible bacterial population (heteroresistance). 5 This peculiar ability could explain the discrepancies in the clarithromycin resistance rates between culture and PCR-based methods and frequent therapeutic failures in presence of clarithromycin susceptibility at the culture. 9 The need of multiple gastric biopsies taken in different gastric sites as been pointed out for bacterial culture, 10 but the biopsy sampling for PCR-based methods to assess H. pylori resistance has been poorly investigated. Our data found that clarithromycin resistant strains were localized exclusively in gastric body in a relevant number of patients. Therefore, by taking only antral biopsies for antibiotic susceptibility testing the actual resistance status would be underestimated. Our finding confirms in adults the results observed in a paediatric population. 11 In agreement with previous investigations, 4, 6, 7 our results found a high prevalence of heteroresistance for clarithromycin in each gastric sites (intraniche heteroresistance). Moreover, the finding of a significant interniche heteroresistance rate (16%) would appears of clinical relevance because of the quite constant involvement of the A2143G mutate genotype. Indeed, such a point mutation has been reported to be strongly associated with a therapeutic failure. [12] [13] [14] In conclusion, our data found that by adding antibiotic susceptibility testing on gastric body mucosa specimens increases H. pylori clarithromycin resistant rate. Moreover, intragastric distribution of H. pylori resistant strains are a highly heterogeneous, both intraniche and interniche.
